Search

everythinglearnresearchcommunity

for

Search:↓

KX-826 is being discussed for hair loss treatment, with users debating between 0.5% and 0.9% solutions and foam. Some report side effects like headaches, while others see no changes; it blocks androgen receptors without reducing DHT levels.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

A user noticed worsening hair loss and is considering treatments. They plan to use finasteride, Rogaine, and a ketoconazole shampoo, and seek advice on their effectiveness and usage.

The user is currently using 0.025% Pantostin but plans to switch to 0.1% Alfatradiol. They will also use high-dose Kx826, high-dose Minoxidil, and aggressive microneedling for hair regrowth.

The user experienced increased hair shedding after one month on 0.25 mg finasteride, despite initial improvement. This shedding may be a normal phase in the hair cycle and could improve in the coming months.

The conversation is about a user seeking help with hair regrowth treatments, specifically mentioning Setipiprant, Minoxidil, Finasteride, and RU58841. The user is trying to contact forum members for guidance on making and using these treatments.

The conversation is about the lack of improvement in hair loss after using Pyrilutamide for 14 weeks, with the original poster unable to use Finasteride due to depression. Replies suggest that Pyrilutamide, like RU58841, may not work for everyone, and a more potent drug is being developed by Kintor.

User "manlycoffee" shares 25-month progress using Dutasteride, RU58841, Minoxidil, Microneedling, Nizoral, T/GEL, and fixing vitamin D levels for hair loss. Users discuss sources, experiences, and side effects of treatments.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

A 23-year-old male shared his 11-month progress using 1.25mg finasteride every other day and Nizoral/Dermazole, reporting reduced hair fall and new hair growth without major shedding. Users discussed the risks of finasteride for younger individuals and suggested consulting a doctor, with some recommending minoxidil as an alternative.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.

The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

Hair loss treatments discussed include cosmeRNA, minoxidil, finasteride, RU58841, and pyrilutamide. Users debate effectiveness, side effects, and upcoming treatments, with some expressing skepticism and others optimism.

A 35-year-old man shares his one-year progress using 1.25 mg oral finasteride and 5% topical minoxidil for hair loss, with no side effects and slight improvement in his front hairline. He also uses keto shampoo twice a week and a 0.5mm roller weekly.

User reports using 0.5mg finasteride, 12.5mg zinc daily, and keto shampoo weekly for hair loss. After one month, there's a slight reduction in hair shedding and no side effects.

The potential hair regrowth benefits of ASC-J9, a synthetic modified version of curcumin that is said to be more effective than Minoxidil and Finasteride. Reports from users suggest good thickening and temple regrowth with topical use at 0.025% concentration.

The user has been using 1mg finasteride, 2% ketoconazole shampoo, vitamins, and growth shampoo for 7.5 months to treat hair loss and is considering switching to 0.5 mg dutasteride due to slight recession and persistent symptoms. Another user commented that the user's temples appear to have improved, especially in the latest photo.

A 21-year-old male is using a Minoxidil (10%) and Finasteride (0.1%) topical solution with a Keraglo Men tablet for hair loss, experiencing positive results without side effects. He advises another user to prepare questions for a dermatologist visit and discusses potential treatment adjustments.

The user achieved significant hair regrowth using only dutasteride, noticing results after 8-9 months despite initial shedding. They did not use minoxidil due to inconvenience but still experienced permanent hair growth.

A 26-year-old man shared his positive results after 10 months of treating male pattern baldness using a regimen that includes Estradiol Enanthate, DHPA, Bicalutamide, Dutasteride, oral and topical Minoxidil, and a dermaroller. He experienced mild gynecomastia and reduced body hair as side effects but was satisfied with the outcome.

A 24-year-old user shared their 12-month progress using 1mg oral finasteride and 5mg oral minoxidil for hair loss, reporting significant improvement after initially starting with 2.5mg minoxidil. They experienced no side effects and noted thicker eyelashes, with results becoming noticeable around the 9th or 10th month.

The conversation discusses the potential availability of a new hair loss treatment, GT20029, on the grey market, with users suggesting it could be within a year but advising against using grey market products due to safety concerns and complexity of the drug.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.

A 29-year-old is using 1mg oral finasteride and 50mg/g topical minoxidil daily for hair loss, with plans to reduce minoxidil use due to greasiness and considering a hair transplant for receding temples. No side effects from finasteride were reported, and many users suggest a transplant may not be necessary due to good hair density.

The conversation discusses Scube3, a seemingly new and obscure treatment for hair loss, with limited information available and a link to a patient intake form.